Dr Proesmans’ Medical Practice

Cardiovascular Disease

Nutritional supplements are used in this practice to support cardiovascular care.
Diet and physical activity remain central to the approach; supplements may provide additional support.

The following nutrients are used in this practice (amounts are daily doses):

Nutrients and daily doses
  • vit K2, 0.180 -0.360 mg
  • vit D, 3000-5000 IU
  • magnesium, 300-500 mg
  • green tea extract, 300-500 mg EGCG
  • curcumin, 500 -1000 mg
  • resveratrol, 100-200 mg
  • omega-3, 1000-2000 mg EPA+DHA
  • vit C, 1000 -2000 mg
  • L-Taurine, 500-1500 mg
  • – Red yeast rice containing 10 mg of monacolin K is used here as an alternative to conventional prescription statins.
  • The 10 mg therapeutic dose described here is obtained from a pharmacy on prescription.

The lower doses sold as nutritional supplements are considered less effective in this approach.
Many of these risk factors can be addressed through a healthy diet and regular physical activity .

Chelation therapy

EDTA chelation therapy is an intravenous treatment using EDTA (ethylenediaminetetraacetic acid), a synthetic compound that binds to metals and minerals. The resulting complex is called a chelate. Heavy metals such as lead, cadmium and mercury have a strong affinity for EDTA.

In the 1940s and 1950s, doctors treating patients with heart disease and lead poisoning observed an improvement in cardiac symptoms.

I have used chelation therapy in my practice for more than twenty years and have administered thousands of infusions. In my experience, it can be useful in patients with narrowing of the blood vessels in the legs and around the heart.

Over the past twenty years, researchers have studied chelation therapy and its effects. A study published in 1993 reported a reduced risk of a further heart attack in patients who received chelation therapy after an initial heart attack. Seventy per cent were symptom-free after three years and reported improved quality of life, including greater ability to climb stairs, less breathlessness, better circulation in the legs and less leg pain.

A double-blind, placebo-controlled study published in 2014 reported benefits from EDTA chelation therapy.
The reported benefits were particularly notable in patients with diabetes, who have an increased risk of cardiovascular disease
. In this group, the reported reduction in the combined outcomes of death, recurrence after surgery and hospital readmission for heart conditions was 43 per cent. Other patients had an 18 per cent reduction in recurrent cardiovascular problems.

In this practice, chelation therapy is also used with a preventive aim in atherosclerosis and after bypass surgery. I consider it as part of an approach intended to reduce the need for further procedures, including surgery for blocked blood vessels in the legs.

In my view, chelation therapy is a valuable adjunct within a comprehensive treatment plan that also includes a healthy diet, exercise, stress reduction and nutritional supplements. It is used alongside conventional medication.

Chelation therapy affects two processes and therefore works in two ways:

  1. EDTA neutralizes free radicals. If free radicals are given free rein under the influence of certain circumstances (smoking, stress, unhealthy diet, air pollution, excessive alcohol consumption, some medicines), they damage cells, resulting in an accelerated ageing process, cancer and atherosclerosis. The production and activity of these free radicals can be promoted by heavy metals in the bloodstream. Chelation therapy ensures that these heavy metals are eliminated.
  2. EDTA not only binds heavy metals, but also calcium. This positively influences the ratio between calcium and magnesium. This has a beneficial effect on the atherosclerosis process.

In this practice, EDTA is administered intravenously with a combination of vitamins, minerals and amino acids. Treatment is given once or twice a week, over twenty to fifty sessions, depending on the indication.

Publications:

1.

Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?

Lamas GA, Ergui I.
Expert Rev Cardiovasc Ther. 2016 Aug;14(8):927-38. doi: 10.1080/14779072.2016.1180977. Epub 2016 May 5.
2.

The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).

Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA.
J Diabetes Complications. 2019 Jul;33(7):490-494. doi: 10.1016/j.jdiacomp.2019.04.005. Epub 2019 Apr
3.

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL.
Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.
4.

Chelation therapy after the trial to assess chelation therapy: results of a unique trial.

Avila MD, Escolar E, Lamas GA.
Curr Opin Cardiol. 2014 Sep;29(5):481-8. doi: 10.1097/HCO.0000000000000096.
5.

Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.

Lamas GA, Navas-Acien A, Mark DB, Lee KL.
J Am Coll Cardiol. 2016 May 24;67(20):2411-2418. doi: 10.1016/j.jacc.2016.02.066.